Skip to main content
Top
Published in: Medical Microbiology and Immunology 1/2011

01-02-2011 | Erratum

Erratum to: Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients

Authors: Stefan Reuter, Mark Oette, Frank Clemens Wilhelm, Bastian Beggel, Rolf Kaiser, Melanie Balduin, Finja Schweitzer, Jens Verheyen, Ortwin Adams, Thomas Lengauer, Gerd Fätkenheuer, Herbert Pfister, Dieter Häussinger

Published in: Medical Microbiology and Immunology | Issue 1/2011

Login to get access

Excerpt

Authors regret that an error was found in Table 1 last line which was already published in online first. …
Metadata
Title
Erratum to: Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients
Authors
Stefan Reuter
Mark Oette
Frank Clemens Wilhelm
Bastian Beggel
Rolf Kaiser
Melanie Balduin
Finja Schweitzer
Jens Verheyen
Ortwin Adams
Thomas Lengauer
Gerd Fätkenheuer
Herbert Pfister
Dieter Häussinger
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 1/2011
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-010-0179-5

Other articles of this Issue 1/2011

Medical Microbiology and Immunology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine